Reagent kit for detecting and quantifying mRNA expression levels for tandem duplications of MLL-PTD gene in clinical material of the patients using polymerase chain reaction (PCR) with real-time hybridization-fluorescence detection.
The kit can be also used to monitor the development of relapse in AML patients.
The kit of reagents is designed to conduct a study in a quantitative format for 24 clinical samples in duplicate (a total of 132 PCR reactions, including controls).
Additional information about the molecular marker:
Cytogenetic abnormalities of the 11q23 genome locus involving MLL (mixed lineage leukemia, ALL-1) gene encoding histone methyltransferase occur in approximately 15% of patients with acute myeloid leukemia (AML). Among them, partial tandem duplications of the MLL gene (MLL-PTD) represent tandem repeats of several exons within the reading frame of the MLL gene which is not detectable by classical cytogenetic methods. The gene duplications are assigned according to the number of repeated exons. This anomaly leads to a change in the resulting transcript, the protein itself, and leads to leukemogenesis due to DNA hypermethylation and epigenetic silencing of tumor suppressor genes. Small amounts of MLL-PTD expression can be found in healthy donors. However, it normally occurs due to unusual variants of alternative splicing, in contrast to AML patients.
MLL-PTD occurs in 5-11% of cases of NC AML, as well as in combination with FLT3-ITD, NPM1 and CEBPA mutations, as well as in 90% of cases of AML with trisomy 11. This anomaly is associated with shorter event-free survival, reduced overall survival, and poor prognosis.
Ordering information:
MLL-PTD RQ Kit, 24 tests Cat.No IG-RQ-16-24
Additiional reagents:
Blood RNA stabilizer medium Cat.No IG-RSB-100
TriZ Reagent Kit Cat.No IG-TRK-100
ReverZyme Kit Cat.No IG-RT-1
Erythrocyte Lysis Solution Cat.No IG-TRL-100
Price: on request
Reagents are for research use only (RUO)